Eli Lilly said Thursday it plans to seek regulatory approval in the first quarter of 2027 for its experimental obesity drug retatrutide after the treatment cleared two additional late-stage clinical trials.
The company detailed that one of the new studies evaluated adults with severe obesity and established cardiovascular disease who did not have diabetes. After 80 weeks of treatment, participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.
